Jump to navigation Jump to search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Gusperimus


Most recent articles on Gusperimus

Most cited articles on Gusperimus

Review articles on Gusperimus

Articles on Gusperimus in N Eng J Med, Lancet, BMJ


Powerpoint slides on Gusperimus

Images of Gusperimus

Photos of Gusperimus

Podcasts & MP3s on Gusperimus

Videos on Gusperimus

Evidence Based Medicine

Cochrane Collaboration on Gusperimus

Bandolier on Gusperimus

TRIP on Gusperimus

Clinical Trials

Ongoing Trials on Gusperimus at Clinical

Trial results on Gusperimus

Clinical Trials on Gusperimus at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gusperimus

NICE Guidance on Gusperimus


FDA on Gusperimus

CDC on Gusperimus


Books on Gusperimus


Gusperimus in the news

Be alerted to news on Gusperimus

News trends on Gusperimus


Blogs on Gusperimus


Definitions of Gusperimus

Patient Resources / Community

Patient resources on Gusperimus

Discussion groups on Gusperimus

Patient Handouts on Gusperimus

Directions to Hospitals Treating Gusperimus

Risk calculators and risk factors for Gusperimus

Healthcare Provider Resources

Symptoms of Gusperimus

Causes & Risk Factors for Gusperimus

Diagnostic studies for Gusperimus

Treatment of Gusperimus

Continuing Medical Education (CME)

CME Programs on Gusperimus


Gusperimus en Espanol

Gusperimus en Francais


Gusperimus in the Marketplace

Patents on Gusperimus

Experimental / Informatics

List of terms related to Gusperimus

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Gusperimus is an immunosuppressive drug. It is a derivative of the antitumor antibiotic spergualin, and inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells.

Gusperimus was developed by Bristol-Myers Squibb. Currently, it is manufactured and sponsored for use as an orphan drug and for clinical studies by the Japanese company Euro Nippon Kayaku. The patent claim (see quotation) is that gusperimus may be useful for a variety of hyperreactive inflammatory diseases such as autoimmune diseases. The drug is available in vials containing 100 mg each.

There is little information about the pharmacokinetic properties of gusperimus.



The European Commission assigned orphan drug status to gusperimus in 2001 for the treatment of Wegener's granulomatosis, a serious form of vasculitis frequently associated with permanent disability and/or fatal outcome. There have been cases of most ill patients resistant to all forms of usual treatment responding very well to gusperimus.


It has been proposed that gusperimus may benefit patients with the neurological disease amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). ALS causes permanent motor deficits and disabilities up to the point that almost all motor functions, including breathing and bladder control, are lost. Patients usually have no intellectual impairments. Currently, there are no results from controlled studies in ALS patients.

There have also been positive and negative anecdotal reports in patients with multiple sclerosis. As with ALS, there are no sufficient studies in MS patients.

Gusperimus may possibly be of use in more common diseases and conditions such as rheumatoid arthritis, Crohn's disease, lupus erythematosus, and the prevention and therapy of transplant rejection or graft-versus-host disease.

Adverse effects

Currently, only provisional and preliminary data about side-effects is available. The following side-effects have been noticed so far:

  • Dysgeusia (=abnormal or bad taste)
  • Drug induced leukopenia (very common)
  • Significant infections related to therapy.

It is not known if therapy with gusperimus may increase the risk of malignant diseases (lymphoma, leukemia, solid tumors), as is the case with other highly potent immunosuppressant agents such as ciclosporin or tacrolimus.


There has been little experience about clinically relevant interactions. These might be:

  • Other immunosuppressant drugs : Risk of infections increased.
  • Myelotoxic drugs like 6-Mercaptopurin : Risk of serious bone marrow damage increased.
  • Certain NSAIDs : Increased risk of hepatotoxic reactions.


Gusperimus is used in therapeutic cycles. The daily dose and the length of each cycle as well as the length of the treatment free interval depend on the degree of leukopenia/neutropenia caused by gusperimus. It is recommended to obtain complete WBC (White Blood Cell) counts during and after each cycle frequently.


Common references are:

  • (+−)-15-Deoxyspergualin,
  • 1-Amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione,
  • 15-Deoxyspergualin,
  • 15-Deoxyspergualin Hydrochloride,
  • 7-{(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amino]-
  • Gusperimus (Trihydrochloride),
  • N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-
  • Spanidin